Multi-cancer blood test: what it costs and what the evidence says

No trial has yet shown that these tests help people live longer. The largest trial so far, the NHS-Galleri trial in England, included more than 140,000 people aged 50 to 77. Everyone gave a blood sample three times, a year apart. Half had their samples tested; the other half had theirs stored and had usual screening only. The trial did not meet its main goal: the number of cancers found at stage 3 or 4, the later stages, was not lower in the tested group. There were somewhat fewer stage 4 cancers, but the researchers have not yet looked at deaths and plan longer follow-up (UCL, June 2026; The ASCO Post, October 2026).

When we checked on 18 Oct 2026, no multi-cancer blood test had been approved by the FDA. In September 2026 an FDA expert panel reviewed one test for adults aged 50 and over, to be used alongside standard screening and not instead of it. The panel voted 7 to 2 that its benefits outweigh its risks. The vote is advice; the FDA makes the decision, which had not been announced. The American Cancer Society says there are no US clinical guidelines for these tests and that they do not replace current screening. The National Cancer Institute says breast, cervical, bowel and lung cancer screening are recommended whether or not someone has one of these tests.

Emerging means: Early human evidence; benefits for healthy ageing not yet shown.